Background

Patientsn = 202 cases between 2007 & 2013

n = 176 🚺 n = 26 🚹 ∅ age: 44.5 (4-84)

Previous medication

Susanne Pannek-Rademacher, Mohinder Singh Jus, Felix Amsler, Jürgen PannekHomöopathie Pannek, Basel, SHI Homöopathie Praxis, Zug, Amsler Consulting, Basel, Neuro-Urologie, Schweizer Paraplegiker-Zentrum, Nottwil,

Switzerland

0

20

40

60

80

100

% Im

prov

emen

t

Indication

First Follow Up (max 2 mths) Last Follow Up (max 6 mths)

Conclusion

Indications/Improvements

Keep in mindCarcinosin

65

44 43 4035

0

10

20

30

40

50

60

70

Lyc Medo Sep Ign Nat-m

Dr. B.K. Bose-Stiftung

43%

34%

23%Cold

Melancholy

Eruption

24%

13% 27%

36%

No control

Change within6 mths

Control and change of remedy

Initial reactions (1st – 3rd month)

.

Our study demonstrates that Carcinosin is a long-acting remedy with a wide range of indications. It often replaced successfully Lycopodium which has certain similarities with Carcinosin. We find it to be a useful polychrest if no active cancer is present.

Apart from the classic monography by Fourbister, only few studies about Carcinosin are available. Therefore we analysed the clinical cases treated with Carcinosin in a single institution

Change within 7-12 mths

No change within 12 mths